Evidence map›Paper›PMID 19909238›Full record

ReviewBiochemical Society transactions2009

Coupling of the NMDA receptor to neuroprotective and neurodestructive events.

Giles E Hardingham

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical Society transactions, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 258 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Early involvement of D-serine in β-amyloid-dependent pathophysiology.Cellular and molecular life sciences : CMLS · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Giles E HardinghamCentre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, UK.
University of Edinburgh · GB

Funding

Biotechnology and Biological Sciences Research Council BB/D011388/1Wellcome Trust 087491Wellcome Trust 87491Wellcome Trust 88156
6 · The paper itself

Abstract

NMDA (N-methyl-D-aspartate) receptors are a subtype of ionotropic glutamate receptor with an important role in the physiology and pathophysiology of central neurons. Inappropriate levels of Ca(2+) influx through the NMDA receptor can contribute to neuronal loss in acute trauma such as ischaemia and traumatic brain injury, as well as certain neurodegenerative diseases such as Huntington's disease. However, normal physiological patterns of NMDA receptor activity can promote neuroprotection against both apoptotic and excitotoxic insults. As a result, NMDA receptor blockade can promote neuronal death outright or render neurons vulnerable to secondary trauma. Thus responses to NMDA receptor activity follow a classical hormetic dose-response curve: both too much and too little can be harmful. There is a growing knowledge of the molecular mechanisms underlying both the neuroprotective and neurodestructive effects of NMDA receptor activity, as well as the factors that determine whether an episode of NMDA receptor activity is harmful or beneficial. It is becoming apparent that oxidative stress plays a role in promoting neuronal death in response to both hyper- and hypo-activity of the NMDA receptor. Increased understanding in this field is leading to the discovery of new therapeutic targets and strategies for excitotoxic disorders, as well as a growing appreciation of the harmful consequences of NMDA receptor blockade.

Indexed as

AntioxidantsApoptosisCalpainClinical Trials as TopicCyclic AMP Response Element-Binding ProteinHumansMitochondriaNerve DegenerationNeurodegenerative DiseasesNeuroprotective AgentsPhosphatidylinositol 3-KinasesProtein IsoformsReactive Nitrogen SpeciesReactive Oxygen SpeciesReceptors, N-Methyl-D-AspartateSignal TransductionAntioxidantsCalpainCyclic AMP Response Element-Binding ProteinNeuroprotective AgentsPhosphatidylinositol 3-KinasesProtein IsoformsReactive Nitrogen SpeciesReactive Oxygen SpeciesReceptors, N-Methyl-D-Aspartate

Identifiers

PMID19909238
PMCPMC2837198
OpenAlexW2133324187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.